Literature DB >> 5052

Susceptibility of pneumococci and Haemophilus influenzae to antibacterial agents.

M Finland, C Garner, C Wilcox, L D Sabath.   

Abstract

Strains of Diplococcus pneumoniae and Haemophilus influenzae were tested for susceptibility to numerous antibiotics by a twofold agar dilution method using an inocula replicator. Undiluted, fully grown broth cultures were used as inocula for both species, and cultures of pneumococci diluted 1:1,000 were also tested. The antibiotics included most of those in common use in the United States as well as some chemical modifications recently approved and others that are under investigation. The most striking aspect of the results was the marked susceptibility of the pneumococci to all the antibiotics tested except the polymyxins and most of the aminoglycoside antibiotics, although some new aminoglycosides were active in quite low concentrations. Some of the strains of pneumococci were of decreased susceptibility to penicillin G (minimal inhibitory concentrations, 0.2 to 0.4 mug/ml), but none were tetracycline resistant, although such strains had been reported previously from this laboratory. The strains of H. influenzae, which were all serologically nontypable, exhibited different patterns of susceptibility to the groups of antibiotics and to the individual chemically related ones. None of these strains (isolated early in 1972) were ampicillin resistant. The most active agents against H. influenzae were: carbenicillin and ampicillin, analogues related to each of them, rifampin, chloramphenicol, and the polymyxins. However, the tetracycline analogues other than tetracycline, some aminoglycosides, notably tobramycin, kanamycin, gentamicin, and verdamicin, erythromycin, and some new lincomycin analogues were also active in low concentrations. Trimethoprim alone was highly active, and in combination with sulfamethoxazole it was even more active and synergistic against strains of both D. pneumoniae and H. influenzae.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 5052      PMCID: PMC429515          DOI: 10.1128/AAC.9.2.274

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Susceptibility of pneumococci to eleven antibiotics in vitro.

Authors:  W F JONES; M FINLAND
Journal:  Am J Med Sci       Date:  1957-03       Impact factor: 2.378

2.  Susceptibility of recently isolated strains of hemophilus influenzae to eleven antibiotics in vitro.

Authors:  B DEL LOVE; M FINLAND
Journal:  J Pediatr       Date:  1954-11       Impact factor: 4.406

3.  In vitro susceptibility of Hemophilus influenzae to seven antibiotics.

Authors:  M FINLAND; C WILCOX
Journal:  Am J Clin Pathol       Date:  1950-04       Impact factor: 2.493

4.  In vitro susceptibility of pneumococci to seven antibiotics.

Authors:  G G JACKSON; T M GOCKE; C WILCOX; M FINLAND
Journal:  Am J Clin Pathol       Date:  1950-03       Impact factor: 2.493

5.  Susceptibility of pneumococci to nine antibiotics.

Authors:  J W Kislak; L M Razavi; A K Daly; M Finland
Journal:  Am J Med Sci       Date:  1965-09       Impact factor: 2.378

6.  Increased resistance to penicillin of pneumococci isolated from man.

Authors:  D Hansman; H Glasgow; J Sturt; L Devitt; R Douglas
Journal:  N Engl J Med       Date:  1971-01-28       Impact factor: 91.245

7.  Increased resistance in the pneumococcus.

Authors:  M Finland
Journal:  N Engl J Med       Date:  1971-01-28       Impact factor: 91.245

Review 8.  Changing patterns of susceptibility of common bacterial pathogens to antimicrobial agents.

Authors:  M Finland
Journal:  Ann Intern Med       Date:  1972-06       Impact factor: 25.391

9.  Susceptibility of common pathogenic bacteria to seven tetracycline antibiotics in vitro.

Authors:  N H Steigbigel; C W Reed; M Finland
Journal:  Am J Med Sci       Date:  1968-03       Impact factor: 2.378

10.  Tetracycline-resistant pneumococci: increasing incidence and cross resistance to newer tetracyclines.

Authors:  K V Gopalakrishna; P I Lerner
Journal:  Am Rev Respir Dis       Date:  1973-10
View more
  16 in total

1.  Penetration of cefamandole into spinal fluid.

Authors:  E A Steinberg; G D Overturf; L J Baraff; J Wilkins
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

2.  Sinusitis, bronchitis, and mycoplasmal pneumonia.

Authors:  G A Pankey
Journal:  Bull N Y Acad Med       Date:  1978-02

3.  Detection and prevalence of pneumococci with increased resistance to penicillin.

Authors:  J M Dixon; A E Lipinski; M E Graham
Journal:  Can Med Assoc J       Date:  1977-11-19       Impact factor: 8.262

Review 4.  World-wide development of antibiotic resistance in pneumococci.

Authors:  P C Appelbaum
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

Review 5.  In vitro antibacterial effects of cephalosporins.

Authors:  J D Williams; F Moosdeen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Quantitative inhibition of Haemophilus influenzae by trimethoprim/sulfamethoxazole.

Authors:  S I Pelton; P A Shurin; J O Klein; M Finland
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

7.  Nitrate reduction: new method for testing the antibiotic susceptibility of Haemophilus influenzae.

Authors:  W Fleming; J Fierer
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

8.  Penetration of spectinomycin into cerebrospinal fluid duirng experimental meningitis.

Authors:  D G Delgado; C J Brau; C K Avent
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

9.  [Tissue penetration of erythromycin (author's transl)].

Authors:  G A Dette
Journal:  Infection       Date:  1979       Impact factor: 3.553

10.  Effect of ampicillin and chloramphenicol alone and in combination on ampicillin-susceptible and -resistant Haemophilus influenzae type B.

Authors:  F S Cole; R S Daum; L Teller; D A Goldmann; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.